Puma Biotechnology, Inc. (Nasdaq:PBYI) announced that the European Commission (EC), has granted marketing authorisation for NERLYNX® (neratinib) for the extended adjuvant treatment of adult patients with early stage hormone receptor positive...
Investors in Puma Biotechnology Inc saw new options become available today, for the October 5th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PBYI options chain for the new October 5th contracts and identified one put and one call contract of particular interest.
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the second quarter ended June 30, 2018.
Investors in Puma Biotechnology Inc saw new options begin trading today, for the September 28th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PBYI options chain for the new September 28th contracts and identified one put and one call contract of particular interest.
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Health Canada has accepted for review the Company's New Drug Submission (NDS) for the medicinal product NERLYNX® (neratinib) for the extended adjuvant treatment of adult...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, and Strata Oncology, Inc.
Puma Biotechnology, Inc. (Nasdaq: PBYI) announced that on June 28, 2018 the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending marketing authorisation for the medicinal product NERLYNX® (neratinib) for the...
Puma Biotechnology, Inc. (Nasdaq: PBYI) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive trend vote recommending the approval of the Marketing Authorisation Application...
Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that interim results from the Phase Ib/II FB-10 clinical trial of Puma's investigational drug PB272 (neratinib) given in combination with the antibody drug conjugate T-DM1...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2018.
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H.
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.
Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, and Pint Pharma International S.
Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced today that NERLYNX® (neratinib) has been included as a recommended treatment option in the latest National Comprehensive Cancer Network...
The following statement is being issued by Robbins Geller Rudman & Dowd LLP regarding the Puma Biotechnology, Inc.
Jim Cramer focuses on Home Depot, Vale, Bank of America, Kraft Heinz, Dominion Energy, Lululemon Athletica, StitchFix, Duke Energy and more.
Jim Cramer says that on Thursday we saw the right stocks rally, even if we didn't see it in the averages. This market had breadth.
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H.
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2017.
Puma Biotechnology, Inc. (Nasdaq: PBYI) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion, recommending the refusal of the...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H.
Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, and CANbridge Life Sciences, a biopharmaceutical company focused on developing Western drug candidates in China and North Asia, have entered into an...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that initial results from the company's ongoing SUMMIT Phase II 'basket' clinical trial of PB272 (neratinib) in patients with tumors harboring...
Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, and Medison Pharma Ltd, Israel's leading commercial partner for innovative pharmaceuticals, have entered into an exclusive agreement under which Medison...
